Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company developing drug candidates for cancer, neurological disorders and other diseases. Its lead candidate, NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel being evaluated in a Phase 2 trial for… From the company’s description.
In fiscal 2025, Relmada Therapeutics, Inc. reported a net loss of $57.39M. Operations used $45.79M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Relmada Therapeutics, Inc. does
In the company’s own words
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company developing drug candidates for cancer, neurological disorders and other diseases. Its lead candidate, NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel being evaluated in a Phase 2 trial for non-muscle-invasive bladder cancer; the company plans to pursue high-risk, BCG-unresponsive and intermediate-risk indications. Its second candidate, sepranolone, is a neurosteroid in development for Prader-Willi syndrome, Tourette syndrome, essential tremor and other disorders associated with excessive GABAergic activity. Relmada acquired sepranolone from Asarina Pharma and licensed NDV-01 from Trigone Pharma in 2025, while ending development of esmethadone and a psilocybin formulation. The company has no approved products, commercial sales or sales and marketing infrastructure. It reported research and development expenses and corporate operations rather than reportable business segments. Relmada has more than 40 issued patents and pending applications related to sepranolone and more than 10 related to NDV-01. Its website is www.relmada.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CORAL GABLES, FL
- Fiscal year end
- December
- CIK
- 1553643
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Relmada Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Relmada Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Relmada Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Relmada Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Relmada Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”